CoChat

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

Chu, Jennifer, Galicia-Vázquez, Gabriela, Cencic, Regina, Mills, John R., Katigbak, Alexandra, Porco, John A., Pelletier, Jerry · 2016 · Cell Reports
Cited by 95

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers. A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A. Small molecule inhibitors targeting eIF4F display promising anti-neoplastic activity in preclinical settings. Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies. Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2016.05.005

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Generation and Characterization of a Rocaglate-Resistant eIF4A1 Allele (A) Schematic illustrating conserved motifs of the DEAD-box helicase family. Sequences of the conserved motifs are denoted with motifs involved in RNA binding highlighted in bold red. The structure of eIF4A indicates it to be dumbbell in shape with two domains (I and II) linked via a flexible linker sequence. The inset shows a ribbon diagram of eIF4A1 (PDB 2ZU6) aligned to eIF4A3 (not shown; PDB 2HYI). The residues targeted for mutagenesis are highlighted and the single-stranded RNA substrate (positioned relative to the eIF4A3 crystal structure) is shown in orange. (B) Coomassie stain of purified recombinant eIF4A1 proteins. (C) Assessment of ATP hydrolysis by recombinant proteins via thin layer chromatography. (D) Kinetics of ATP hydrolysis by eIF4A1 and eIF4A1(F163L). ATPase assays were performed with 1 µg protein and varying ATP concentrations. Graph represents the Michaelis-Menten fit from two independent experiments. (E) RNA binding activity of eIF4A1 and eIF4A1(F163L) using [32P]-labeled RNA generated from pSP/CAT (see Supplemental Experimental Procedures). Assays were performed in the presence of 0.5% DMSO or 1 µM silvestrol and the retained eIF4A:RNA complexes are set relative to DMSO controls. n = 3 biological replicates performed in triplicate ±SEM; *p < 0.001. (F) Quantitation of eIF4A1 and eIF4A1(F163L) helicase activity performed with 0.5 µg recombinant eIF4A1 and an 11-nt radiolabeled RNA duplex in the presence of DMSO or 50 µM silvestrol. n = 3 biological replicates ±SEM; *p < 0.05. (G) DSF analysis of eIF4A1 or eIF4A1(F163L) in the presence of DMSO or (−)-SDS-1-021.
Figure 1 Generation and Characterization of a Rocaglate-Resistant eIF4A1 Allele (A) Schematic illustrating conserved motifs of the DEAD-box helicase family. Sequences of the conserved motifs are denoted with motifs involved in RNA binding highlighted in bold red. The structure of eIF4A indicates it to be dumbbell in shape with two domains (I and II) linked via a flexible linker sequence. The inset shows a ribbon diagram of eIF4A1 (PDB 2ZU6) aligned to eIF4A3 (not shown; PDB 2HYI). The residues targeted for mutagenesis are highlighted and the single-stranded RNA substrate (positioned relative to the eIF4A3 crystal structure) is shown in orange. (B) Coomassie stain of purified recombinant eIF4A1 proteins. (C) Assessment of ATP hydrolysis by recombinant proteins via thin layer chromatography. (D) Kinetics of ATP hydrolysis by eIF4A1 and eIF4A1(F163L). ATPase assays were performed with 1 µg protein and varying ATP concentrations. Graph represents the Michaelis-Menten fit from two independent experiments. (E) RNA binding activity of eIF4A1 and eIF4A1(F163L) using [32P]-labeled RNA generated from pSP/CAT (see Supplemental Experimental Procedures). Assays were performed in the presence of 0.5% DMSO or 1 µM silvestrol and the retained eIF4A:RNA complexes are set relative to DMSO controls. n = 3 biological replicates performed in triplicate ±SEM; *p < 0.001. (F) Quantitation of eIF4A1 and eIF4A1(F163L) helicase activity performed with 0.5 µg recombinant eIF4A1 and an 11-nt radiolabeled RNA duplex in the presence of DMSO or 50 µM silvestrol. n = 3 biological replicates ±SEM; *p < 0.05. (G) DSF analysis of eIF4A1 or eIF4A1(F163L) in the presence of DMSO or (−)-SDS-1-021.CC BY-NC-ND · PubMed Central
Figure 2 Ectopic Expression of eIF4A1(F163L) Confers Resistance to Rocaglates in Mammalian Cells (A) Schematic diagram of RCV designed to simultaneously express an shRNA-resistant His6-eIF4A1 allele while suppressing endogenous eIF4A1. (B) Representative western blot of NIH/3T3 cells transduced with RCVs. The dashed line separates the two sets of western blots. (C) Viability assay of RCV-transduced NIH/3T3 cells. Cells were exposed to the indicated concentrations of silvestrol and relative viability was assessed 6 days later by sulforhodamine B (SRB). n = 2 biological replicates performed in duplicates ±SEM. (D) Competition assay of transduced NIH/3T3 cells. Transduced cells (GFP+) were mixed with parental cells (GFP−) and cultured in the presence of 20 nM silvestrol. The percentage of GFP+ cells was determined on the indicated days. n = 2 biological replicates performed in triplicate ±SEM. (E) Cells expressing eIF4A1(F163L) are resistant to translation inhibition by silvestrol. Transduced cells were incubated with the indicated concentrations of silvestrol for 1 hr and labeled with [35S]-methionine/cysteine during the last 15 min. n = 4 biological replicates ±SEM. (F) Polysome profiles of transduced NIH/3T3 cells following exposure to 200 nM silvestrol for 30 min. P/M represents the polysome/monosome ratio. n = 3 biological replicates ±SEM. See also Figure S1.
Figure 2 Ectopic Expression of eIF4A1(F163L) Confers Resistance to Rocaglates in Mammalian Cells (A) Schematic diagram of RCV designed to simultaneously express an shRNA-resistant His6-eIF4A1 allele while suppressing endogenous eIF4A1. (B) Representative western blot of NIH/3T3 cells transduced with RCVs. The dashed line separates the two sets of western blots. (C) Viability assay of RCV-transduced NIH/3T3 cells. Cells were exposed to the indicated concentrations of silvestrol and relative viability was assessed 6 days later by sulforhodamine B (SRB). n = 2 biological replicates performed in duplicates ±SEM. (D) Competition assay of transduced NIH/3T3 cells. Transduced cells (GFP+) were mixed with parental cells (GFP−) and cultured in the presence of 20 nM silvestrol. The percentage of GFP+ cells was determined on the indicated days. n = 2 biological replicates performed in triplicate ±SEM. (E) Cells expressing eIF4A1(F163L) are resistant to translation inhibition by silvestrol. Transduced cells were incubated with the indicated concentrations of silvestrol for 1 hr and labeled with [35S]-methionine/cysteine during the last 15 min. n = 4 biological replicates ±SEM. (F) Polysome profiles of transduced NIH/3T3 cells following exposure to 200 nM silvestrol for 30 min. P/M represents the polysome/monosome ratio. n = 3 biological replicates ±SEM. See also Figure S1.CC BY-NC-ND · PubMed Central
Figure 3 Cas9-Mediated Editing of Eif4a1 (A) Strategy for introducing the Eif4a1(F163L) mutant allele. The sequence of two sgRNAs targeting exon 5 and the partial sequence of the ssODN donor are shown. The PAMs are shaded, and the nucleotide changes in the ssODN donor that abolishes their presence are indicated in red. The targeted TTT (F) codon is indicated by a dashed orange box, and engineered CTC (L) change in the ssODN donor is indicated in green. (B) Sequence analysis of the PCR products from eIF4A1em1JP and eIF4A1em2JP cells indicating loss of the wild-type Eif4a1 allele and composition of mutant alleles. (C) Relative translation rates in Rosa26em1JP, eIF4A1em1JP, eIF4A1em2JP cells transduced with the indicated retroviruses. (D) Western blot assessing His6-eIF4A1 and total eIF4A1 in the cell lines used in (C). (E) CETSA of Rosa26em1JP and eIF4A1em1JP cells. Cells were incubated with 1 µM (−)-SDS-1-021 or DMSO for 1 hr at 37°C and heated at the indicated temperatures for 3 min. Soluble lysates were prepared and used for western blotting. n = 4 biological replicates ±SEM. See also Figure S2.
Figure 3 Cas9-Mediated Editing of Eif4a1 (A) Strategy for introducing the Eif4a1(F163L) mutant allele. The sequence of two sgRNAs targeting exon 5 and the partial sequence of the ssODN donor are shown. The PAMs are shaded, and the nucleotide changes in the ssODN donor that abolishes their presence are indicated in red. The targeted TTT (F) codon is indicated by a dashed orange box, and engineered CTC (L) change in the ssODN donor is indicated in green. (B) Sequence analysis of the PCR products from eIF4A1em1JP and eIF4A1em2JP cells indicating loss of the wild-type Eif4a1 allele and composition of mutant alleles. (C) Relative translation rates in Rosa26em1JP, eIF4A1em1JP, eIF4A1em2JP cells transduced with the indicated retroviruses. (D) Western blot assessing His6-eIF4A1 and total eIF4A1 in the cell lines used in (C). (E) CETSA of Rosa26em1JP and eIF4A1em1JP cells. Cells were incubated with 1 µM (−)-SDS-1-021 or DMSO for 1 hr at 37°C and heated at the indicated temperatures for 3 min. Soluble lysates were prepared and used for western blotting. n = 4 biological replicates ±SEM. See also Figure S2.CC BY-NC-ND · PubMed Central
Figure 4 Cas9-Mediated Editing of the Eif4a1 Locus Confirms the Drug-Target Hypothesis (A) Colony formation assay of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells in the presence of silvestrol. (B) Response of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP xenografts in vivo to silvestrol. On the indicated days, mice were treated with silvestrol (0.2 mg/kg) following tumor appearance. n = 6–7 mice/cohort ±SEM. (C) Bar graph of the percentage of apoptotic nuclei from tumor sections. Three hours before harvesting of tumors, mice were treated with vehicle or 0.2 mg/kg silvestrol. n = 2 biological replicates (with ~7,000 nuclei analyzed per tumor) ±SD; *p < 0.05; ns, not significant. (D) Polysome profiles of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells exposed to 10 nM silvestrol for 1 hr. (E) Distribution of mRNAs in polysome fractions shown in (D). See also Figures S3 and S4.
Figure 4 Cas9-Mediated Editing of the Eif4a1 Locus Confirms the Drug-Target Hypothesis (A) Colony formation assay of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells in the presence of silvestrol. (B) Response of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP xenografts in vivo to silvestrol. On the indicated days, mice were treated with silvestrol (0.2 mg/kg) following tumor appearance. n = 6–7 mice/cohort ±SEM. (C) Bar graph of the percentage of apoptotic nuclei from tumor sections. Three hours before harvesting of tumors, mice were treated with vehicle or 0.2 mg/kg silvestrol. n = 2 biological replicates (with ~7,000 nuclei analyzed per tumor) ±SD; *p < 0.05; ns, not significant. (D) Polysome profiles of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells exposed to 10 nM silvestrol for 1 hr. (E) Distribution of mRNAs in polysome fractions shown in (D). See also Figures S3 and S4.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 19

  1. Bordeleau, 2008, Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model, J. Clin. Invest., 118, 2651
  2. Chu, 2016, Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status, Mol. Cancer Ther., 15, 136, 10.1158/1535-7163.MCT-15-0409 · DOI
  3. Elfakess, 2011, Unique translation initiation of mRNAs-containing TISU element, Nucleic Acids Res., 39, 7598, 10.1093/nar/gkr484 · DOI · Paper page
  4. Elliott, 1998, Gene conversion tracts from double-strand break repair in mammalian cells, Mol. Cell. Biol., 18, 93, 10.1128/MCB.18.1.93 · DOI · Paper page
  5. Galicia-Vázquez, 2012, A cellular response linking eIF4AI activity to eIF4AII transcription, RNA, 18, 1373, 10.1261/rna.033209.112 · DOI · Paper page
  6. Graff, 2007, Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity, J. Clin. Invest., 117, 2638, 10.1172/JCI32044 · DOI · Paper page
  7. Hong, 2011, A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer, Clin. Cancer Res., 17, 6582, 10.1158/1078-0432.CCR-11-0430 · DOI · Paper page
  8. Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc., 9, 2100, 10.1038/nprot.2014.138 · DOI · Paper page
  9. Lin, 2012, Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis, Cell Rep., 1, 325, 10.1016/j.celrep.2012.02.010 · DOI · Paper page
  10. Lorsch, 1998, The DEAD box protein eIF4A. 1. A minimal kinetic and thermodynamic framework reveals coupled binding of RNA and nucleotide, Biochemistry, 37, 2180, 10.1021/bi972430g · DOI · Paper page
  11. Niesen, 2007, The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability, Nat. Protoc., 2, 2212, 10.1038/nprot.2007.321 · DOI · Paper page
  12. Pan, 2014, Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species, Nat. Prod. Rep., 31, 924, 10.1039/C4NP00006D · DOI · Paper page
  13. Polier, 2012, The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2, Chem. Biol., 19, 1093, 10.1016/j.chembiol.2012.07.012 · DOI · Paper page
  14. Rajalingam, 2005, Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration, Nat. Cell Biol., 7, 837, 10.1038/ncb1283 · DOI · Paper page
  15. Sadlish, 2013, Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex, ACS Chem. Biol., 8, 1519, 10.1021/cb400158t · DOI · Paper page
  16. Smurnyy, 2014, DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells, Nat. Chem. Biol., 10, 623, 10.1038/nchembio.1550 · DOI
  17. Truitt, 2015, Differential requirements for eIF4E dose in normal development and cancer, Cell, 162, 59, 10.1016/j.cell.2015.05.049 · DOI · Paper page
  18. Yang, 2013, Optimization of scarless human stem cell genome editing, Nucleic Acids Res., 41, 9049, 10.1093/nar/gkt555 · DOI · Paper page
  19. Yoder-Hill, 1993, The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A, J. Biol. Chem., 268, 5566, 10.1016/S0021-9258(18)53358-5 · DOI · Paper page

Cited by

See all 95

Metadata

Authors
Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A., & Pelletier, J.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2016-06
Volume
15
Issue
11
Pages
2340-2347
ISSN
2211-1247
Cited by
95
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. https://app.cochat.ai/papers/10.1016/j.celrep.2016.05.005
The paper
Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A., & Pelletier, J. (2016). CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. Cell Reports. https://doi.org/10.1016/j.celrep.2016.05.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.